EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Effect of Obesity on the Exposure of Long-acting Cabotegravir and Rilpivirine: A Modeling Study

Sara Bettonte, Mattia Berton, Felix Stader, Manuel Battegay, Catia Marzolini iD

Clinical Infectious Diseases · 16.08.2024 · 79 (2) · 477-486

DOI: 10.1093/cid/ciae060 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Infectious Diseases, online erschienen am 03.02.2024. Verfasst von Sara Bettonte und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases and Hospital Epidemiology, Departments of Medicine and Clinical Research, University Hospital Basel, Basel, Switzerla…. Hauptthemen laut MEDLINE: Rilpivirine, Pyridones, HIV Infections, Obesity. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swiss National Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Obesity is increasingly prevalent among people with human immunodeficiency virus (HIV, PWH). Obesity can reduce drug exposure; however, limited data are available for long-acting (LA) antiretrovirals. We performed in silico trials using physiologically based pharmacokinetic (PBPK) modeling to determine the effect of obesity on the exposure of LA cabotegravir and rilpivirine after the initial injection and after multiple injections.

Methods

Our PBPK model was verified against available clinical data for LA cabotegravir and rilpivirine in normal weight/ overweight (body mass index [BMI] <30 kg/m2) and in obese (BMI >30 kg/m2). Cohorts of virtual individuals were generated to simulate the exposure of LA cabotegravir/rilpivirine up to a BMI of 60 kg/m2. The fold change in LA cabotegravir and rilpivirine exposures (area under the curve [AUC]) and trough concentrations (Cmin) for monthly and bimonthly administration were calculated for various BMI categories relative to normal weight (18.5–25 kg/m2).

Results

Obesity was predicted to impact more cabotegravir than rilpivirine with a decrease in cabotegravir AUC and Cmin of >35% for BMI >35 kg/m2 and in rilpivirine AUC and Cmin of >18% for BMI >40 kg/m2 at steady-state. A significant proportion of morbidly obese individuals were predicted to have both cabotegravir and rilpivirine Cmin below the target concentration at steady-state with the bimonthly administration, but this was less frequent with the monthly administration.

Conclusions

Morbidly obese PWH are at risk of presenting suboptimal Cmin for cabotegravir/rilpivirine after the first injection but also at steady-state particularly with the bimonthly administration. Therapeutic drug monitoring is advised to guide dosing interval adjustment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RilpivirinePyridonesHIV InfectionsObesityAnti-HIV AgentsHumansMaleAdultFemaleMiddle AgedBody Mass IndexComputer SimulationDiketopiperazines

Stichwörter der Autor:innen

PBPK modelingcabotegravirlong-actingobesityrilpivirine

Substanzen

RilpivirinecabotegravirPyridonesAnti-HIV AgentsDiketopiperazines

Autor:innen und Institutionen

  • Division of Infectious Diseases and Hospital Epidemiology, Departments of Medicine and Clinical Research, University Hospital Basel, Basel, Switzerland.
  • Faculty of Medicine, University of Basel, Basel, Switzerland.
  • Certara UK Limited, Sheffield, United Kingdom.
  • Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom.
  • Service and Laboratory of Clinical Pharmacology, Department of Laboratory Medicine and Pathology, University Hospital Lausanne and University of Lausanne, Lausanne, Switzerland.

ORCID-Profile: Catia Marzolini

Förderung

  • Swiss National Foundation

Zitieren

APA

Bettonte, S., Berton, M., Stader, F., Battegay, M., & Marzolini, C. (2024). Effect of Obesity on the Exposure of Long-acting Cabotegravir and Rilpivirine: A Modeling Study. Clinical Infectious Diseases, 79(2), 477-486. https://doi.org/10.1093/cid/ciae060

Vancouver

Bettonte S, Berton M, Stader F, Battegay M, Marzolini C. Effect of Obesity on the Exposure of Long-acting Cabotegravir and Rilpivirine: A Modeling Study. Clinical Infectious Diseases. 2024;79(2):477-486. doi:10.1093/cid/ciae060

BibTeX
@article{Bettonte2024,
  author = {Bettonte, Sara and Berton, Mattia and Stader, Felix and Battegay, Manuel and Marzolini, Catia},
  title = {Effect of Obesity on the Exposure of Long-acting Cabotegravir and Rilpivirine: A Modeling Study},
  journal = {Clinical Infectious Diseases},
  year = {2024},
  volume = {79},
  number = {2},
  pages = {477--486},
  doi = {10.1093/cid/ciae060}
}
Kostenlos starten →